Monoclonal antibodies for Alzheimer’s disease, like the drug called Aduhelm, attach to aberrant proteins thought to be one cause of the disease, but they only stand to benefit a small number of the people who might be at risk. That’s …
Only a small percentage of people are candidates for monoclonal antibodies to treat Alzheimer’s disease, Elizabeth Tracey reports Read More »